Dopamine Receptor Agonists and Hypertension

  • Mustafa F. Lokhandwala
  • Richard J. Barrett
Part of the New Horizons in Therapeutics book series (NHTH)


Dopamine receptor agonists exert pronounced cardiovascular actions that result from activation of specific dopamine receptors located at various sites within the cardiovascular system (Clark, 1981; Cavero et al., 1982a,b; Lokhandwala and Barrett, 1981, 1982, 1983). Although dopamine is the prototype of dopamine receptor agonists, in addition to the activation of dopamine receptors, this catecholamine also possesses agonistic actions at a and β adrenoceptors (Goldberg, 1972; Lokhandwala and Barrett, 1982). Therefore, attempts have been made to develop Compounds that are selective at dopamine receptors and do not exert significant actions at other adrenoceptors. As discussed in several chapters of this volume, one of the major aims in developing these compounds is for the therapeutic potential they offer in the treatment of various cardiovascular and renal disorders.


Dopamine Receptor Ergot Alkaloid Dopamine Receptor Agonist Antihypertensive Action Mean Blood Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ackerman, D. M., Weinstock, J., Weibelhaus, V. D., and Berkowitz, B., 1982, Renal vasodilators and hypertension, Drug Dev. Res. 2:283–297.CrossRefGoogle Scholar
  2. Barrett, R. J., and Lokhandwala, M. F., 1981a, Presynaptic dopamine receptor stimulation in the cardiovascular actions of lergotrile, J. Pharmacol. Exp. Ther. 217:660–665.Google Scholar
  3. Barrett, R. J., and Lokhandwala, M. F., 1981b, The role of alpha adrenergic and dopamine receptor activation in the cardiovascular effects of pergolide, Fed. Proc. 40:315.Google Scholar
  4. Barrett, R. J., Ginos, J. Z., and Lokhandwala, M. F., 1982, Evaluation of peripheral dopamine receptor and a-adrenoceptor blocking activity of sulpiride, Eur. J. Pharmacol. 79:273–281.PubMedCrossRefGoogle Scholar
  5. Cavero, I., Massingham, R., and Lefevre-Borg, F., 1982a, Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents: SubClassification and functional description, Life Sci. 31:939–948.CrossRefGoogle Scholar
  6. Cavero, I., Massingham, R., and Lefevre-Borg, F., 1982b, Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents: Sites and mechanisms of action of dopamine receptor agonists, Life Sci. 31:1059–1069.CrossRefGoogle Scholar
  7. Clark, B. J., 1979, Cardiovascular effects of ergot alkaloids, J. Pharmacol. (Paris) 10:439–453.Google Scholar
  8. Clark, B. J., 1981, Dopamine receptors and the cardiovascular system, Postgrad. Med. J. 57(Suppl 1):45–54.PubMedCrossRefGoogle Scholar
  9. Cox, R. H., and Bagshaw, R. J., 1980, Effects of anesthesia on carotid sinus reflex control of arterial hemodynamics in the dog, Am. J. Physiol. 239:H681–H691.PubMedGoogle Scholar
  10. Goldberg, L. I., 1972, Cardiovascular and renal actions of dopamine: Potential clinical applications, Pharmacol. Rev. 24:1–29.PubMedGoogle Scholar
  11. Greenacre, J. K., Teychenne, P. F., Petrie, A., Calne, D. B., Leigh, P. N., and Reid, J. L., 1976, The cardiovascular effects of bromocriptine in parkinsonism, Br. J. Clin. Pharmacol. 3:571–574.PubMedCrossRefGoogle Scholar
  12. Hahn, R. A., 1981, Inhibitory effects of pergolide on peripheral adrenergic neurotransmission in spontaneously hypertensive rats, Life Sci. 29:2501–2509.PubMedCrossRefGoogle Scholar
  13. Hahn, R. A., and Farrell, S. K., 1981, Inhibition of peripheral adrenergic neurotransmission by lergotrile in spontaneously hypertensive rats, Life Sci. 28:2497–2504.PubMedCrossRefGoogle Scholar
  14. Kaye, S. B., Shaw, K. M., and Ross, E. J., 1976, Bromocriptine and hypertension, Lancet 1:1176–1177.PubMedCrossRefGoogle Scholar
  15. Kirchheim, H. R., 1976, Systemic arterial baroreeeptor reflexes, Physiol. Rev. 56:100–176.PubMedGoogle Scholar
  16. Kondo, S., Ebihara, A., Suzuki, H., and Saruta, T., 1981, Role of dopamine in the regulation of blood pressure and the renin-angiotensin-aldosterone system in conscious rats, Clin. Sci. 61:235s–237s.PubMedGoogle Scholar
  17. Langer, S. Z., 1980, Presynaptic regulation of the release of catecholamines, Pharmacol. Rev. 32:337–362.PubMedGoogle Scholar
  18. Laubie, M., and Schmitt, H., 1979, Destruction of nucleus tractus solitari in the dog: Comparison with sinoaortic denervation, Am. J. Physiol. 236:H736–H743.PubMedGoogle Scholar
  19. Laubie, M., Schmitt, H., and Falq, E., 1977, Dopamine receptors in the femoral vascular bed of the dog as mediators of a vasodilator and sympathoinhibitory effect, Eur. J. Pharmacol. 42:307–310.PubMedCrossRefGoogle Scholar
  20. Lokhandwala, M. F., 1979, Analysis of the effects of bromocriptine on blood pressure and sympathetic nerve function, Eur. J. Pharmacol. 56:253–256.PubMedCrossRefGoogle Scholar
  21. Lokhandwala, M. F., and Barrett, R. J., 1981, Pharmacological role of presynaptic dopamine receptors in the cardiovascular actions of dopaminergic agents, in: Central Nervous System Mechanisms in Hypertension (J. P. Buckley and C. M. Ferrario, eds.), Raven Press, New York, pp. 203–213.Google Scholar
  22. Lokhandwala, M. F., and Barrett, R. J., 1982, Cardiovascular dopamine receptors: Physiological, pharmacological and therapeutic implications, J. Autonom. Pharmacol. 3:189–215.CrossRefGoogle Scholar
  23. Lokhandwala, M. F., and Barrett, R. J., 1983, Dopamine receptor agonists in cardiovascular therapy, Drug Dev. Res. 3:299–310.CrossRefGoogle Scholar
  24. Lokhandwala, M. F., Tadepalli, A. S., and Jandhyala, B. S., 1979, Cardiovascular actions of bromocriptine: Evidence for a neurogenic mechanism, J. Pharmacol. Exp. Ther. 211:620–625.PubMedGoogle Scholar
  25. Snyder, D. W., Doba, N., and Reis, D. J., 1978, Regional distribution of blood flow during arterial hypertension produced by lesions of the nucleus tractus solitarii in rats, Circ. Res. 42:87–91.PubMedCrossRefGoogle Scholar
  26. Sved, A. F., and Fernstrom, J. D., 1980, Evidence for a peripheral dopaminergic mechanism in the antihypertensive action of lergotrile, Life Sci. 27:349–354.PubMedCrossRefGoogle Scholar
  27. Yen, T. T., Stamm, N. B., and Clemens, J. A., 1979, Pergolide, a potent dopaminergic antihypertensive, Life Sci. 25:209–216.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Mustafa F. Lokhandwala
    • 1
  • Richard J. Barrett
    • 1
  1. 1.Department of Pharmacology and Institute for Cardiovascular Studies, College of PharmacyUniversity of Houston Central CampusHoustonUSA

Personalised recommendations